Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.
Stephens
R L
RL
University of Kansas Medical Center.
Goodman
P
P
Crawford
E D
ED
Spicer
C F
CF
Lowe
B A
BA
Ahmann
F R
FR
Chapman
R
R
Natale
R B
RB
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D017290:Menogaril; D009621:Nogalamycin / Q000031:analogs & derivatives / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D017290:Menogaril; D009621:Nogalamycin; D003630:Daunorubicin